Cervical Cancer Diagnostics Market Size, Scope And Growth 2025 To 2034

Unlock 20% Off Global Market Reports Using Code ONLINE20 – Stay Informed on Trade Policies, Market Growth, and Key Disruptors

What Is the Forecasted Market Size of the Cervical Cancer Diagnostics Market by 2029?
The cervical cancer diagnostics market size has grown strongly in recent years. It will grow from $9.27 billion in 2024 to $9.76 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to increased awareness and screening programs, hpv vaccination, technological advancements, aging population.

The cervical cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $12.29 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing hpv-related cancers, emerging markets, molecular testing advances, telemedicine and remote screening. Major trends in the forecast period include hpv testing, liquid-based cytology, automation and digital pathology, screen-and-treat programs.

Claim your free report sample now:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3285&type=smp

Which Factors Are Driving Growth in the Cervical Cancer Diagnostics Market?
The rising adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to drive the market for cervical cancer diagnostics. Increasing awareness among women about cervical cancer along with the emphasis by worldwide cancer organizations and governments on early testing for detecting cervical cancer and preventing it contributes to the growth of the market. For instance, in July 2024, according to the Centers for Disease Control and Prevention, a US-based government agency in 2021, the United States reported 12,536 new cases of cervical cancer, while in 2022, the disease resulted in 4,051 fatalities among women. The rising adoption of cervical cancer diagnostic tests and emphasis on early diagnosis propels the growth of the cervical cancer diagnostics market.

What Are the Key Segments in the Cervical Cancer Diagnostics Market?
The cervical cancer diagnosticsmarket covered in this report is segmented –

1) By Diagnostic Test: Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage, Other Diagnostic Tests
2) By Age Group: Below 21, Age between 21 to 29, Age between 30 to 65, Above 65
3) By End User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Diagnostic Centers

Subsegments:
1) By Pap Smear Test: Conventional Pap Smear, Liquid-Based Pap Smear
2) By HPV Test: DNA-Based HPV Test, RNA-Based HPV Test, Hybrid Capture HPV Test, Other HPV Tests
3) By Colposcopy: Standard Colposcopy, Digital Colposcopy, Optical Colposcopy
4) By Biopsy And Endocervical Curettage: Punch Biopsy, Endocervical Curettage (ECC), Cone Biopsy, Colposcopic Biopsy
5) By Other Diagnostic Tests: Visual Inspection With Acetic Acid (VIA), Cervical Cytology Testing, Blood Tests, Other Specialty Tests

Which Emerging Trends Are Driving the Cervical Cancer Diagnostics Market?
Major companies operating in the cervical cancer diagnostics market are focusing on developing technologically innovative solutions, such as HPV self-collection solutions for cervical cancer, to increase accessibility to screening and enhance early detection rates. The HPV self-collection solution for cervical cancer refers to a method that allows individuals to collect their own samples for testing human papillomavirus (HPV), which is a major cause of cervical cancer. For instance, in May 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, received FDA approval for its HPV self-collection solution, a significant advancement in cervical cancer screening that enhances accessibility for individuals, particularly those in underserved populations. This innovative method allows women to privately collect vaginal samples for analysis using Roche's Cobas molecular HPV test, supporting the World Health Organization's goal of eliminating cervical cancer by 2030. The approval follows the successful IMPACT trial, which demonstrated the solution's effectiveness across diverse demographics.

Who Are the Leading Players in the Cervical Cancer Diagnostics Market?
Major companies operating in the cervical cancer diagnostics market include Abbott Laboratories, Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Zilico Ltd., Guided Therapeutics Inc., Thermo Fisher Scientific Inc., Carl Zeiss AG, OncoHealth Corporation, Arbor Vita Corporation, Micromedic Technologies Ltd., Trovagene Inc., Roche Diagnostics, Nucleix Ltd., BGI Genomics Co. Ltd., Cepheid, Exact Sciences Corporation, Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., PerkinElmer Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation

Get the full cervical cancer diagnostics market report here:
https://www.thebusinessresearchcompany.com/report/cervical-cancer-diagnostics-global-market-report

What Are the Key Regional Trends in the Cervical Cancer Diagnostics Market?
North America was the largest region in the cervical cancer diagnostics market in 2024 Asia-Pacific was the second largest region in the cervical cancer diagnostics market. The regions covered in the cervical cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company